Stockscreener 앱 받기
2.01
0.50%
0.010
전일 마감가:
$2.00
열려 있는:
$1.95
하루 거래량:
29,567
Relative Volume:
2.33
시가총액:
$3.11M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+16.18%
1개월 성능:
+0.00%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$1.9452
$2.04
1주일 범위
$1.6313
$2.14
52주 변동 폭
$1.6313
$2.14
Vivosim Labs Inc Stock (VIVS) Company Profile
명칭
Vivosim Labs Inc
전화
858-224-1000
주소
11555 SORRENTO VALLEY ROAD, SAN DIEGO
VIVS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VIVS
Vivosim Labs Inc
|
2.01 | 3.11M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.12 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.39 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
657.73 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.61 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.07 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Vivosim Labs Inc Stock (VIVS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2018-12-13 | 개시 | H.C. Wainwright | Buy |
| 2017-11-10 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2017-01-25 | 개시 | Raymond James | Outperform |
| 2015-08-11 | 다운그레이드 | Cantor Fitzgerald | Buy → Hold |
| 2015-06-29 | 개시 | Jefferies | Buy |
| 2015-06-29 | 개시 | Piper Jaffray | Overweight |
모두보기
Vivosim Labs Inc 주식(VIVS)의 최신 뉴스
Organovo Holdings, Inc. Announces Board Appointments - marketscreener.com
Organovo: Fiscal Q2 Earnings Snapshot - marketscreener.com
Organovo Holdings, Inc. and BICO Reach Licensing Agreement on Bioprinting Patents - marketscreener.com
VivoSim Labs introduces AI-driven drug testing models By Investing.com - Investing.com Canada
VIVS: Riding the Market Waves of Growth and Decline in 2023 - investchronicle.com
Two new option listings and one option delisting on April 24th - TipRanks
VivoSim Announces Emergence from Stealth Mode To Provide Technol - GuruFocus
VivoSim Labs introduces AI-driven drug testing models - Investing.com
VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market - The Manila Times
VivoSim Labs, Inc. Emerges from Stealth Mode to Revolutionize Drug Discovery with Non-Animal Toxicology Models Following FDA Initiative - Nasdaq
VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from - Bluefield Daily Telegraph
FDA Shift Powers VivoSim's Game-Changing Drug Testing Tech: 50% Cost Reduction Target - Stock Titan
Organovo (ONVO) Rebrands to VivoSim Labs with New Ticker 'VIVS' | ONVO Stock News - GuruFocus
Organovo announces VivoSim to carry forward 3D bioprinting, legacy tech - TipRanks
Organovo rebrands as VivoSim Labs, debuts new ticker - Investing.com
VivoSim to Carry Forward Organovo 3D Bioprinting | ONVO Stock Ne - GuruFocus
Organovo Holdings Announces Transition to VivoSim Labs - TipRanks
VivoSim to Carry Forward Organovo 3D Bioprinting - The Manila Times
Organovo Holdings Inc Name Change To VivoSim Labs Effective April 24, 2025 - TradingView
Strategic Transformation: Organovo Becomes VivoSim Labs to Accelerate 3D Bioprinting Innovation - Stock Titan
Organovo gets upfront payments following sale of its FXR Program to Lilly - Seeking Alpha
Organovo Announces Close Of Sale Of FXR Program To Eli Lilly And Company - marketscreener.com
Eli Lilly stock rises after deal with Organovo (ONVO:NASDAQ) - Seeking Alpha
ONVO Stock Quote Price and Forecast - CNN
ORGANOVO HOLDINGS, INC. : Other Events, Financial Statements and Exhibits (form 8-K) - marketscreener.com
Organovo Holdings, Inc. Announces Executive Changes - marketscreener.com
ONVOOrganovo Holding Latest Stock News & Market Updates - Stock Titan
Vivosim Labs Inc (VIVS) 재무 분석
Vivosim Labs Inc (VIVS)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.52%
0.52%
자본화:
|
볼륨(24시간):